Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Naruge

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
In Vivo (Athens, Greece)|September 3, 2020
Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203Naohiro Okano, Kiyomi Hana, Daisuke Naruge, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 23, 2017
[Geriatric Oncology]Satoko Maeno, Fumio Nagashima, Daisuke Naruge, et al.
Cancer Chemotherapy and Pharmacology|July 12, 2018
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumorsJunji Furuse, Takayasu Kurata, Naohiro Okano, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 23, 2021
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene PolymorphismsAkitomo Yokokawa, Shun Kaneko, Sayuri Endo, et al.
Anticancer Research|February 10, 2017
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract CancerShiho Arima, Kyoko Shimizu, Tomoyoshi Okamoto, et al.
Investigational New Drugs|August 12, 2015
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumorsAkiyoshi Kasuga, Kazuhiko Nakagawa, Fumio Nagashima, et al.
Liver Cancer|July 11, 2020
Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular CarcinomaRyota Matsuki, Kirio Kawai, Yutaka Suzuki, et al.
Journal of Palliative Medicine|March 23, 2018
Factors Influencing Cancer Patients' Choice of End-of-Life Care PlaceMaika Natsume, Kiyotaka Watanabe, Satoko Matsumoto, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
In Vivo (Athens, Greece)|September 3, 2020
Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203Naohiro Okano, Kiyomi Hana, Daisuke Naruge, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 23, 2017
[Geriatric Oncology]Satoko Maeno, Fumio Nagashima, Daisuke Naruge, et al.
Cancer Chemotherapy and Pharmacology|July 12, 2018
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumorsJunji Furuse, Takayasu Kurata, Naohiro Okano, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 23, 2021
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene PolymorphismsAkitomo Yokokawa, Shun Kaneko, Sayuri Endo, et al.
Anticancer Research|February 10, 2017
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract CancerShiho Arima, Kyoko Shimizu, Tomoyoshi Okamoto, et al.
Investigational New Drugs|August 12, 2015
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumorsAkiyoshi Kasuga, Kazuhiko Nakagawa, Fumio Nagashima, et al.
Liver Cancer|July 11, 2020
Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular CarcinomaRyota Matsuki, Kirio Kawai, Yutaka Suzuki, et al.
Journal of Palliative Medicine|March 23, 2018
Factors Influencing Cancer Patients' Choice of End-of-Life Care PlaceMaika Natsume, Kiyotaka Watanabe, Satoko Matsumoto, et al.
Pageof 2